美沙拉秦治疗溃疡性结肠炎26例疗效观察

Oral Mesalazine for Ulcerative Colitis：Therapeutic Effect Observation of 26 Cases

为观察美沙拉秦治疗溃疡性结肠炎的疗效和安全性，将49例经内镜确诊为轻、中度溃疡性结肠炎急性期患者分为治疗组和对照组，治疗组26例采用美沙拉秦口服治疗，对照组23例采用柳氮磺吡啶口服治疗。服药8周后复查内镜，治疗4周和8周后对药物疗效进行评价。结果显示，在服药4刷和8周末，治疗组患者主观评价为明显好转者分别为53．9％和73．1％，对照组分别为21．9％和52．2％（P〈0．05）。治疗组服药8周内镜下显效率为65．3％，有效率为23．1％，总有效率为88．4％，对照组显效率为30．4％，有效率为34．8％，总有效率为64．8％；治疗组显效率、总有效率均显著高于对照组（P〈0．05）。治疗组总体评价为很好者（42．3％）显著高于对照组（4．4‰）（P〈0．05）。结果表明，美沙拉秦是一种治疗溃疡性结肠炎安全有效的药物。

In order to observe the clinical efficacy and safety of Mesalazine in treating ulcerative colitis,49 patients with mild to moderate ulcerative colitis confirmed by endoscope were randomly divided into two groups： treatment group（ n =26） and control group（ n =23）. Mesalazine was given to the treatment group orally,while Sulfasalazine to the control group. After 8 week treatment,all patients received endoscopic examination again,and clinical efficacy was assessed at the 4th week and 8th week after treatment. The results showed that the subjective estimate significant improvement rate was 53.9% and 73.1% in the treat ment group,21.9% and 52.2% in the controls （ P 〈0.05）. Endoscopic examination showed that treatment group had an obvious effect rate of 65.3%,effective rate of 23. 1%,and total effective rate of 88.4 %,while the control group had 30.4 %,34.8% and 64.8%. Treatment groupwas superior to the controls in obvious effect rate and total effective rate （ P 〈0.05）. In the treatment group,the overall evaluation of patients being very good accounted for 42.3% ,which was significantly higher than that in the control group （4.4%） （ P〈0.05 ） . It is concluded that Mesalazine is a safe and effective drug for ulcerative colitis .